106 related articles for article (PubMed ID: 6444419)
1. Circulating heparan sulfate proteoglycan anticoagulant from a patient with a plasma cell disorder.
Khoory MS; Nesheim ME; Bowie EJ; Mann KG
J Clin Invest; 1980 Mar; 65(3):666-74. PubMed ID: 6444419
[TBL] [Abstract][Full Text] [Related]
2. Circulating heparan sulfate anticoagulant in a patient with a fatal bleeding disorder.
Palmer RN; Rick ME; Rick PD; Zeller JA; Gralnick HR
N Engl J Med; 1984 Jun; 310(26):1696-9. PubMed ID: 6233489
[TBL] [Abstract][Full Text] [Related]
3. [Heparan sulfate proteoglycan of endothelial cells: homocysteine suppresses anticoagulant active heparan sulfate in cultured endothelial cells].
Nishinaga M; Shimada K
Rinsho Byori; 1994 Apr; 42(4):340-5. PubMed ID: 8176841
[TBL] [Abstract][Full Text] [Related]
4. An anticoagulant dermatan sulfate proteoglycan circulates in the pregnant woman and her fetus.
Andrew M; Mitchell L; Berry L; Paes B; Delorme M; Ofosu F; Burrows R; Khambalia B
J Clin Invest; 1992 Jan; 89(1):321-6. PubMed ID: 1729278
[TBL] [Abstract][Full Text] [Related]
5. Circulating dermatan sulfate and heparan sulfate/heparin proteoglycans in children undergoing liver transplantation.
Mitchell L; Superina R; Delorme M; Vegh P; Berry L; Hoogendoorn H; Andrew M
Thromb Haemost; 1995 Sep; 74(3):859-63. PubMed ID: 8571311
[TBL] [Abstract][Full Text] [Related]
6. A heparin-like anticoagulant as part of global abnormalities of plasma glycosaminoglycans in a patient with transitional cell carcinoma.
Horne MK; Chao ES; Wilson OJ; Scialla SJ; Lynch MA; Kragel PJ
J Lab Clin Med; 1991 Sep; 118(3):250-60. PubMed ID: 1919298
[TBL] [Abstract][Full Text] [Related]
7. Structural characterization and functional effects of a circulating heparan sulfate in a patient with hepatocellular carcinoma.
Wages DS; Staprans I; Hambleton J; Bass NM; Corash L
Am J Hematol; 1998 Aug; 58(4):285-92. PubMed ID: 9692391
[TBL] [Abstract][Full Text] [Related]
8. Characterization and hormonal modulation of anticoagulant heparan sulfate proteoglycans synthesized by rat ovarian granulosa cells.
Hosseini G; Liu J; de Agostini AI
J Biol Chem; 1996 Sep; 271(36):22090-9. PubMed ID: 8703018
[TBL] [Abstract][Full Text] [Related]
9. Heparin-like anticoagulant associated with multiple myeloma and neutralized with protamine sulfate.
Torjemane L; Guermazi S; Ladeb S; Ben Romdhane N; Lakhal A; Abdelkefi A; Ben Othman T; Ben Abdelhadhim A
Blood Coagul Fibrinolysis; 2007 Apr; 18(3):279-81. PubMed ID: 17413766
[TBL] [Abstract][Full Text] [Related]
10. Perlecan is responsible for thrombospondin 1 binding on the cell surface of cultured porcine endothelial cells.
Vischer P; Feitsma K; Schön P; Völker W
Eur J Cell Biol; 1997 Aug; 73(4):332-43. PubMed ID: 9270876
[TBL] [Abstract][Full Text] [Related]
11. Isolation and partial characterization of a cell-surface heparan sulfate proteoglycan from embryonic rat spinal cord.
Giuseppetti JM; McCarthy JB; Letourneau PC
J Neurosci Res; 1994 Apr; 37(5):584-95. PubMed ID: 8028039
[TBL] [Abstract][Full Text] [Related]
12. The B16F10 cell receptor for a metastasis-promoting site on laminin-1 is a heparan sulfate/chondroitin sulfate-containing proteoglycan.
Engbring JA; Hoffman MP; Karmand AJ; Kleinman HK
Cancer Res; 2002 Jun; 62(12):3549-54. PubMed ID: 12068003
[TBL] [Abstract][Full Text] [Related]
13. Heparin/heparan sulfate anticoagulant glycosaminoglycans in human plasma of healthy donors: preliminary study on a small group of recruits.
Cecchi F; Pacini S; Gulisano M; Macchi C; Catini C; Lova RM; Fuzzi G; Ruggiero M; Vannucchi S
Blood Coagul Fibrinolysis; 2008 Jul; 19(5):349-54. PubMed ID: 18600081
[TBL] [Abstract][Full Text] [Related]
14. Structural basis of beta 1 integrin-mediated cell adhesion to a large heparan sulfate proteoglycan from basement membranes.
Battaglia C; Aumailley M; Mann K; Mayer U; Timpl R
Eur J Cell Biol; 1993 Jun; 61(1):92-9. PubMed ID: 7693469
[TBL] [Abstract][Full Text] [Related]
15. Expression of human perlecan domain I as a recombinant heparan sulfate proteoglycan with 20-kDa glycosaminoglycan chains.
Graham LD; Whitelock JM; Underwood PA
Biochem Biophys Res Commun; 1999 Mar; 256(3):542-8. PubMed ID: 10080934
[TBL] [Abstract][Full Text] [Related]
16. Anticoagulant activity in cell-free peritoneal fluid of an experimental pancreatic ascites tumor.
Ts'ao C; Galluzzo TS; Hart SJ; Ng AS; Sorenson PG; Subbarao V
Thromb Haemost; 1985 Dec; 54(4):768-72. PubMed ID: 3003955
[TBL] [Abstract][Full Text] [Related]
17. Acidic and basic fibroblast growth factor bind with differing affinity to the same heparan sulfate proteoglycan on BALB/c 3T3 cells: implications for potentiation of growth factor action by heparin.
Brown KJ; Hendry IA; Parish CR
J Cell Biochem; 1995 May; 58(1):6-14. PubMed ID: 7543903
[TBL] [Abstract][Full Text] [Related]
18. Membrane-anchored proteoglycans of mouse macrophages: P388D1 cells express a syndecan-4-like heparan sulfate proteoglycan and a distinct chondroitin sulfate form.
Yeaman C; Rapraeger AC
J Cell Physiol; 1993 Nov; 157(2):413-25. PubMed ID: 8227171
[TBL] [Abstract][Full Text] [Related]
19. Serpin-independent anticoagulant activity of a fucosylated chondroitin sulfate.
Glauser BF; Pereira MS; Monteiro RQ; Mourão PA
Thromb Haemost; 2008 Sep; 100(3):420-8. PubMed ID: 18766257
[TBL] [Abstract][Full Text] [Related]
20. Capillary electrophoresis and enzyme solid phase assay for examining the purity of a synthetic heparin proteoglycan-like conjugate and identifying binding to basic fibroblast growth factor.
Dimitrellos V; Lamari FN; Militsopoulou M; Kanakis I; Karamanos NK
Biomed Chromatogr; 2003 Jan; 17(1):42-7. PubMed ID: 12583005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
